Who Gets the Vaccine First? Furious Lobbying by Interest Groups – The New York Times

Related Articles:

• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Parkinson’s, Flu Shots & You October 11, 2019 October signals the beginning of influenza season, a time when many wonder, “Should I get a flu shot?”. The short answer is, yes, but for people living with Parkinson’s, there can be additional concerns or questions. Let’s take a look at what you and your care team can do to prepare for the 2019-2020 flu season. Who Should Get a…
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. December 12, 2020 Related ArticlesSafety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020 Dec 08;: Authors: Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM,…
• UNS’ Investigational Vaccine UB-312 Holds Potential to Prevent Parkinson’s, Other Neurological Diseases, Data Show November 16, 2018 An investigational vaccine being developed by United Neuroscience (UNS) presented several advantages over traditional vaccines to treat progressive disorders, such as Parkinson’s disease, according to preclinical data. The vaccine, called UB-312, was more selective to prevent toxic aggregates of alpha-synuclein in mouse models of the disease. These latest findings were discussed during the Parkinson’s UK Research Conference 2018 held in York, England. The…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Parkinson’s Vaccine Triggers Solid Immune Response, Phase 1 Clinical Trial Shows June 15, 2017 AFFiRiS’s new Parkinson’s vaccine, AFFITOPE PD03A, triggered a solid immune response against the alpha-Synuclein (aSyn) protein associated with the disease, according to a Phase 1 clinical trial. Patients also tolerated the therapy well, researchers said. Werner Poewe, a professor at Austria’s Medical University Insbruck, presented the results at the 21stInternational Congress of Parkinson’s Disease and Movement Disorders in Vancouver, Canada, June 4-8. He is part of…
• Is a vaccine for Parkinson’s disease possible? November 3, 2020 As the world awaits an effective vaccine for SARS-CoV2 (the virus that causes COVID-19), vaccines and vaccination are at the front and center of the news and in our minds. A vaccine is a substance that is introduced into the body in order to stimulate the immune system to provide protection against a particular disease. Did you know that many…
• Is a vaccine for Parkinson’s disease possible? November 3, 2020 As the world awaits an effective vaccine for SARS-CoV2 (the virus that causes COVID-19), vaccines and vaccination are at the front and center of the news and in our minds. A vaccine is a substance that is introduced into the body in order to stimulate the immune system to provide protection against a particular disease. Did you know that many…
• Why should I go to a Parkinson’s disease support group? October 15, 2019 Why should I go to a Parkinson’s disease support group? Support groups play a vital role in the lives of many people with Parkinson’s disease (PD) and APDA plays a vital role in providing access to support groups around the country. In general terms, a support group is a collection of participants who meet on a regular basis, facilitated by…
• FDA Response Bolsters Affiris’ Plans for Potential Parkinson’s Vaccine Affitope January 29, 2020 The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company and provided guidance related to designing the upcoming trial. Based on that response, Affiris intends to…
• Affiris Announces Phase 2 Study of Potential Parkinson’s Vaccine January 14, 2020 Affiris is preparing for a Phase 2 clinical trial to test Affitope (PD01A), an experimental medicine that, if successful, could lead to a vaccine against  Parkinson’s disease. Affitope triggers the production of antibodies — molecules that recognize specific targets — against alpha-synuclein, a protein found in the brain that may be involved in transmitting information between neurons. While its precise function remains…
• Vaccine breakthrough November 10, 2020 Tuesday 10 November 2020Vaccines are hard to develop. They typically take 10-15 years to bring to market at huge cost and effort. Despite their widespread use, there is still only one disease to have been vaccinated off the face of the Earth. Smallpox was the first disease to be vaccinated against, famously by English country doctor Edward Jenner experimenting on…
• Potential Parkinson’s Vaccine, Affitope PD01A, Safe and Possibly Effective in Long-term, Phase 1 Trial Series Finds May 18, 2018 Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data from a series of four consecutive clinical trials show. Results from the so-called AFF008 study program were recently presented at the Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD) in Torino, Italy, by Werner Poewe, chairman of the Department of Neurology at the…
• Parkinson's Disease Vaccine in First Tests in Patients May 9, 2016 Austrian biotech company AFFiRiS AG has begun testing a new Parkinson’s vaccine in a clinical Phase I trial in Austria by an EU-funded consortium. The new vaccine targets a protein called alpha-Synuclein, which plays a key role in the onset and progression of Parkinson’s disease. Unlike current treatments that provide only symptomatic improvements of the severe motor symptoms of the…
• Parkinson's Disease Vaccine in First Tests in Patients May 9, 2016 Austrian biotech company AFFiRiS AG has begun testing a new Parkinson’s vaccine in a clinical Phase I trial in Austria by an EU-funded consortium. The new vaccine targets a protein called alpha-Synuclein, which plays a key role in the onset and progression of Parkinson’s disease. Unlike current treatments that provide only symptomatic improvements of the severe motor symptoms of the…
• Parkinson's Disease News - Editor's Picks (Archive 2016.07) September 30, 2016 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed Pedaling for Parkinson’sThat is what it’s like living with Parkinson’s disease. Parkinson’s disease is a chronic, neurodegenerative disorder in which the loss of cells in various parts of the brain leaves people less able to control their…
• E90 subunit vaccine protects mice from Zika virus infection and microcephaly. June 6, 2019 Related ArticlesE90 subunit vaccine protects mice from Zika virus infection and microcephaly. Acta Neuropathol Commun. 2018 08 10;6(1):77 Authors: Zhu X, Li C, Afridi SK, Zu S, Xu JW, Quanquin N, Yang H, Cheng G, Xu Z Abstract Zika virus (ZIKV) became a global threat due to its unprecedented outbreak and its association with congenital malformations such as microcephaly in…
• "国家利益高于一切" – National Interest Comes Before All Else March 23, 2020 What is it about the ant way of life that has stood the test of time so well? All ants belong to extended families, and carry their prey home to share. Unselfishness is the rule. Everything they do is for their colony’s good.     Bill Mason Trends show that much of Europe and North America are about to experience the complete shock…
• How China Avoided Collapse March 23, 2020 “国家利益高于一切” – National Interest Comes Before All Else Trends show that much of Europe and North America are about to experience the complete shock to society that the corona virus brought to China, Italy and Iran. Though some nations took swift and decisive action to ensure the best possible outcome for their people, others stood for too long, unwilling to…
• How China Avoided Collapse March 23, 2020 “国家利益高于一切” – National Interest Comes Before All Else Trends show that much of Europe and North America are about to experience the complete shock to society that the corona virus brought to China, Italy and Iran. Though some nations took swift and decisive action to ensure the best possible outcome for their people, others stood for too long, unwilling to…
• How China Avoided Collapse March 23, 2020 “国家利益高于一切” – National Interest Comes Before All Else Trends show that much of Europe and North America are about to experience the complete shock to society that the corona virus brought to China, Italy and Iran. Though some nations took swift and decisive action to ensure the best possible outcome for their people, others stood for too long, unwilling to…
• How China Avoided Collapse March 23, 2020 “国家利益高于一切” – National Interest Comes Before All Else Trends show that much of Europe and North America are about to experience the complete shock to society that the corona virus brought to China, Italy and Iran. Though some nations took swift and decisive action to ensure the best possible outcome for their people, others stood for too long, unwilling to…